Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20192018201720162015201420132012201120102009200820072006 ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics Jan 03, 2019 Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Dec 27, 2018 Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs Nov 14, 2018 Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 09, 2018 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018 Nov 07, 2018 New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers Nov 06, 2018 Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting Nov 06, 2018 Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets Oct 30, 2018 Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Oct 02, 2018 Nektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham Oct 01, 2018 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »